Imprimis Pharmaceuticals (immy) Acquires Intellectual Property Assets From Buderer Drug Company
6/17/2013 11:13:25 AM
More...
|
Imprimis Pharmaceuticals (immy) to Present at the National Investment Banking Association (NIBA) Conference June 18th in New York City
6/14/2013 12:51:58 PM
More...
|
Imprimis Pharmaceuticals (immy) Concludes Type C Meeting at the FDA
4/18/2013 9:53:46 AM
More...
|
Imprimis Pharmaceuticals (immy) Announces Underwriter Exercise of Over-Allotment Option
3/13/2013 10:03:54 AM
More...
|
Imprimis Pharmaceuticals (immy) Out Licenses Its Proprietary IP to ResolutionMD for Cosmeceutical Products
3/4/2013 9:54:39 AM
More...
|
Imprimis Pharmaceuticals (immy) Announces Successful Results From Its Pharmacokinetic Study for Its Impracor Topical NSAID
2/19/2013 10:30:08 AM
More...
|
Imprimis Pharmaceuticals (immy) Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
2/8/2013 9:30:09 AM
More...
|
Imprimis Pharmaceuticals (immy) to Begin New Study of Its Topical Analgesic Drug
9/19/2012 10:53:04 AM
More...
|
Imprimis Pharmaceuticals (immy) Names Two Experts to Its Science and Regulatory Board
9/13/2012 10:02:23 AM
More...
|
Imprimis Pharmaceuticals (immy) Names Two Experts to Its Science and Regulatory Board
9/10/2012 10:17:55 AM
More...
|
|